CoMo Consortium

MSc for Modelling in Global Health: Applications now open for 2025/26 academic year. Take this opportunity to further your career in public health. tinyurl.com/mrxvkyvh

Our NEW training programme, Strategic Modelling for Public Health Policy, launches today. Aimed at entry level modellers working in a range of sectors. Courses start 24 April. For more information and to sign up click here: como-international.github.io/training/train…

OPPORTUNITY: We are recruiting for a Deputy Programme Director on the MSc in Modelling for Global Health. Apply by 28 November @NDMOxford @OxfordMedSci @TropMedOxford linkedin.com/jobs/view/3757…

VACANCY: We are recruiting for a Teaching Co-ordinator on the MSc in Modelling for Global Health. Apply by 3 Nov linkedin.com/jobs/view/3741… @NDMOxford @OxfordMedSci @TropMedOxford

VACANCY: Do you have a PhD/DPhil in a topic related to global health modelling with experience of teaching and research? We are recruiting for a Teaching Co-ordinator on the MSc in Modelling for Global Health. Apply by 28 June👇my.corehr.com/pls/uoxrecruit… @NDMOxford @OxfordMedSci

New blog in Nature Microbiology Community: Behind the paper: “Potential health and economic impacts of dexamethasone treatment for patients with COVID-19” naturemicrobiologycommunity.nature.com/posts/behind-t…

Vaccines dominate the headlines but the significance of this cost-effective option for the management of severe COVID-10 patients and its potential to save lives is key. New research by @rimashretta @rjaaguas @lisawhite1000 @PeterHorby @MartinLandray

3/3 Essential now to perform clinical research in low- and middle-income countries with limited access to oxygen and/or ventilators.

2/3 NEW study by @ComoConsortium researchers in Nature Comms nature.com/articles/s4146… estimates the potential number of lives saved and life-years gained if this treatment were to be rolled out in the UK and globally, as well as the cost-effectiveness of this intervention.

1/3 In June 2020, the #recoverytrial a large, multicenter, randomized, open-label trial performed in the UK reported that dexamethasone administered for 10 days reduced mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively.

A widely used drug for many years that has played a major role in decreasing COVID-19 mortality recently and is incredibly cost effective. Unfortunately was not recommended for use earlier in th the pandemic. nature.com/articles/s4146…

National consortium to study threats of new SARS-CoV-2 variants medsci.ox.ac.uk/news/national-…

Brand new course! MSc Modelling for Global Health. A full-time 1 year programme to train a new modellers with cutting edge multi-disciplinary skills supporting developing global health systems. @oxunistudents @uniofoxford @OxfordMedSci ox.ac.uk/admissions/gra…

New paper in @GlobalHealthBMJ by @rimashretta @lisawhite1000 @rjaaguas shows how participatory modelling approaches, with in-country experts playing an essential iterative policy-facing role, facilitates decision making to curb #COVID19 gh.bmj.com/content/5/12/e…

The UK lockdown is estimated to cost GBP 18b a month. The insights of economics could have helped and would be essential in any future pandemic. iea.org.uk/publications/t… via @iealondon

New blog on Covid-19 vaccines by @ComoConsortium researchers @rimashretta @lisawhite1000 and Ricardo Aguas @NDMOxford @UniofOxford